Sign In
About ASHM | Careers | Your Cart Shoppint Cart
    Skip Navigation LinksASHM Internet Home > Janssen-Cilag Pty Ltd announce the deregistration and discontinuation of supply of INCIVO® (Telaprevir) from 1 September 2015

    Janssen-Cilag Pty Ltd announce the deregistration and discontinuation of supply of INCIVO® (Telaprevir) from 1 September 2015

    News |
      |
    GPs; Specialists; Nurses; Prescribers |
      |
    People Living With BBV |
    ASHM |
      |
      |
     

    Janssen-Cilag Pty Ltd have advised that INCIVO® (Telaprevir) will be removed from the Pharmaceutical Benefits Scheme and deregistered on 1 September 2015 due to the availability of other direct-acting anti-virals (DAAs) as alternatives.

    Telaprevir is a first generation direct-acting anti-viral medication that is used in combination with peg-interferon and ribavirin to treat hepatitis C genotype 1. Telaprevir has been replaced within the clinical setting by OLYSIO® (simeprevir), a second generation DAA with an improved safety and tolerability profile.

    Please refer to the INCIVO® Product Information (until I September 2015) should you need any information on this product.

    If you have any questions regarding the removal of INCIVO® from the PBS or the deregistration, please contact Janssen Medical Information on 1800 226 334 or medinfo@janau.jnj.com.        

    Please enter a valid E-mail.
    This must match your colleagues E-mail.
    Please enter your name.
    Please enter a valid email.
    This must match your email.